Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Short term Debt (2021 - 2024)

Precision Biosciences (DTIL) has disclosed Short term Debt for 3 consecutive years, with $22.5 million as the latest value for Q2 2024.

  • Quarterly Short term Debt rose 0.79% to $22.5 million in Q2 2024 from the year-ago period, while the trailing twelve-month figure was $22.5 million through Jun 2024, up 0.79% year-over-year, with the annual reading at $22.4 million for FY2023, N/A changed from the prior year.
  • Short term Debt for Q2 2024 was $22.5 million at Precision Biosciences, roughly flat from $22.5 million in the prior quarter.
  • The five-year high for Short term Debt was $22.5 million in Q2 2024, with the low at $2.4 million in Q2 2021.
  • Average Short term Debt over 3 years is $16.7 million, with a median of $22.4 million recorded in 2023.
  • Peak annual rise in Short term Debt hit 0.79% in 2024, while the deepest fall reached 0.79% in 2024.
  • Over 3 years, Short term Debt stood at $2.5 million in 2021, then soared by 813.28% to $22.4 million in 2023, then rose by 0.37% to $22.5 million in 2024.
  • According to Business Quant data, Short term Debt over the past three periods came in at $22.5 million, $22.5 million, and $22.4 million for Q2 2024, Q1 2024, and Q4 2023 respectively.